Key Findings
The study established the feasibility of intrasplenic cell transplantation via the splenic artery using an operational immunodeficient pig (OIDP) model. Following the transplantation of human-induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs), human albumin was detected in pig serum 2 weeks post-transplantation. Histological analysis at 4 weeks identified colonies of cells positive for human albumin and vimentin. Additionally, transplantation of quantum-dot-labeled human iTPC-derived islets resulted in the detection of human C-peptide in the serum after a glucose tolerance test, with histological confirmation of insulin-producing cells in the spleen.
Technical Details
The OIDP model involved thymectomy and the administration of tacrolimus, mycophenolate mofetil, and prednisolone via a gastric tube. To prevent rejection without removing the organ, splenic immune cells were inactivated by perfusing mitomycin C through a temporal extracorporeal circuit that isolated the spleen from systemic circulation. This circuit also served as the route for cell delivery. The researchers used adult microminiature pigs (27- to 29-mo-old, 20–24 kg) for iPSC-HLC transplantation and domestic piglets (5-wk-old, approximately 10 kg) for iTPC-derived islet transplantation.
Background and Context
While intrahepatic transplantation (such as the Edmonton protocol) is a standard for islets, researchers sought an alternative ectopic site. The spleen was selected due to its sinusoidal vascular structure, which mimics that of the liver. The study utilized iPSC-HLCs derived from hepatic fibroblasts of pediatric drug-induced fulminant hepatitis patients and iTPC-derived islets produced from human pancreatic cells containing 80% or more islets.
Significance and Outlook
The spleen offers several advantages as a transplantation site: it typically remains healthy during liver disease or diabetes, it can be surgically removed if tumors form without risking the patient’s life, and it allows for preconditioning via extracorporeal circulation. This proof-of-concept study provides a preclinical basis for assessing the therapeutic potential of progenitor-derived cells via a vascular approach that closely mimics clinical procedures.
Source: https://doi.org/10.1097/txd.0000000000002025
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



